Propofol and α2-Agonists Attenuate Microglia Activation and Restore Mitochondrial Function in an In Vitro Model of Microglia Hypoxia/Reoxygenation
Authors:
- Lucia LonghitanoLLLucia Longhitano
- Alfio DistefanoADAlfio Distefano
- Paolo MurabitoPMPaolo Murabito
- Marinella AstutoMAMarinella Astuto
- Anna NicolosiANAnna Nicolosi
- Giovanni BuscemaGBGiovanni Buscema
- Filippo SanfilippoFilippo Sanfilippo
- Giuseppe LazzarinoGiuseppe Lazzarino
- Angela Maria AmoriniAngela Maria Amorini
- Andrea BruniABAndrea Bruni
- Eugenio GarofaloEGEugenio Garofalo
- Daniele TibulloDaniele Tibullo
Open Access
- 28 August 2022
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 11 (9) , 1682
Abstract
Cerebrovascular ischemia is a common clinical disease encompassing a series of complex pathophysiological processes in which oxidative stress plays a major role. The present study aimed to evaluate the effects of Dexmedetomidine, Clonidine, and Propofol in a model of hypoxia/reoxygenation injury. Microglial cells were exposed to 1%hypoxia for 3 h and reoxygenated for 3 h, and oxidative stress was measured by ROS formation and the expression of inflammatory process genes. Mitochondrial dysfunction was assessed by membrane potential maintenance and the levels of various metabolites involved in energetic metabolism. The results showed that Propofol and α2-agonists attenuate the formation of ROS during hypoxia and after reoxygenation. Furthermore, the α2-agonists treatment restored membrane potential to values comparable to the normoxic control and were both more effective than Propofol. At the same time, Propofol, but not α2-agonists, reduces proliferation (Untreated Hypoxia = 1.16 ± 0.2, Untreated 3 h Reoxygenation = 1.28 ± 0.01 vs. Propofol hypoxia = 1.01 ± 0.01 vs. Propofol 3 h Reoxygenation = 1.12 ± 0.03) and microglial migration. Interestingly, all of the treatments reduced inflammatory gene and protein expressions and restored energy metabolism following hypoxia/reoxygenation (ATP content in hypoxia/reoxygenation 3 h: Untreated = 3.11 ± 0.8 vs. Propofol = 7.03 ± 0.4 vs. Dexmedetomidine = 5.44 ± 0.8 vs. Clonidine = 7.70 ± 0.1), showing that the drugs resulted in a different neuroprotective profile. In conclusion, our results may provide clinically relevant insights for neuroprotective strategies in intensive care units.Keywords
Funding Information
- Piano di Incentivi per la ricercar di Ateneo (2020/2022, 2014-2020-E66C18001240007)
- PON AIM R&I (2020/2022, 2014-2020-E66C18001240007)
This publication has 48 references indexed in Scilit:
- Effect of Clonidine (an Antihypertensive Drug) Treatment on Oxidative Stress Markers in the Heart of Spontaneously Hypertensive RatsOxidative Medicine and Cellular Longevity, 2013
- Sensing and reacting to microbes through the inflammasomesNature Immunology, 2012
- Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during ApoptosisImmunity, 2012
- Erratum: A role for mitochondria in NLRP3 inflammasome activationNature, 2011
- Propofol Inhibits Aquaporin 4 Expression Through a Protein Kinase C–Dependent Pathway in an Astrocyte Model of Cerebral Ischemia/ReoxygenationAnesthesia & Analgesia, 2009
- The NALP3 inflammasome is involved in the innate immune response to amyloid-βNature Immunology, 2008
- Clinical Practice Advisory: Emergency Department Procedural Sedation With PropofolAnnals of Emergency Medicine, 2007
- The cellular response in neuroinflammation: The role of leukocytes, microglia and astrocytes in neuronal death and survivalClinical Neuroscience Research, 2006
- Cystamine inhibits transglutaminase and caspase‐3 cleavage in glutamate‐exposed astroglial cellsJournal of Neuroscience Research, 2003
- The Effect of the α2-Agonist Dexmedetomidine and the N-Methyl-d-Aspartate Antagonist S(+)-Ketamine on the Expression of Apoptosis-Regulating Proteins After Incomplete Cerebral Ischemia and Reperfusion in RatsAnesthesia & Analgesia, 2003